首页> 美国卫生研究院文献>Oncology Letters >Detection of urinary survivin using a magnetic particles-based chemiluminescence immunoassay for the preliminary diagnosis of bladder cancer and renal cell carcinoma combined with LAPTM4B
【2h】

Detection of urinary survivin using a magnetic particles-based chemiluminescence immunoassay for the preliminary diagnosis of bladder cancer and renal cell carcinoma combined with LAPTM4B

机译:基于磁性粒子的化学发光免疫分析检测尿中存活素结合LAPTM4B初步诊断膀胱癌和肾细胞癌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of the present study was to establish a simple step magnetic particles (MPs) based chemiluminescence enzyme immunoassay (CLEIA) for the detection of urinary survivin, and to investigate the diagnostic value of urinary survivin and lysosome-associated protein transmembrane-4β (LAPTM4B) in bladder cancer (BC) and renal cell carcinoma (RCC). The MPs-based CLEIA was developed on the basis of a double antibodies sandwich immunoreaction and luminol-H2O2 chemiluminescence system. The parameters of the method were optimized and evaluated. Urine samples were obtained from 200 BC patients, 81 RCC patients and 114 healthy individuals, and the MPs-based CLEIA method was employed to detect their urinary survivin. At the same time, the urinary LAPTM4B levels of the BC patients, RCC patients and the healthy controls were measured. The diagnostic efficiency of urinary survivin and LAPTM4B in BC and RCC was evaluated separately and jointly. A one-step MPs-based CLEIA for the detection of urinary survivin with good accuracy and precision was established. The signals were dependent on survivin concentrations in the range, 0 to 200 ng/ml, and the detection limit was 0.949 ng/ml. The areas under the receiver operating characteristic curves (AUC) were 0.771 in BC and 0.763 in RCC for urinary survivin. Urinary survivin was correlated with the tumor stage (P=0.002), lymph node metastasis (P=0.017), distant metastasis (P=0.005) and tumor size (P=0.02) of BC; however, no association with the clinicopathological parameters in RCC was observed. The AUCs for urinary LAPTM4B were 0.738 in BC and 0.704 in RCC, respectively. The AUCs for them combined were 0.842 in BC and 0.920 in RCC. The MPs-based CLEIA was performed well in the detection of urinary survivin. Urinary survivin and LAPTM4B could serve as potential biomarkers for the preliminary diagnosis of BC and RCC, and in combination they a achieved a greater diagnostic performance.
机译:本研究的目的是建立基于步进磁粉(MPs)的化学发光酶免疫分析(CLEIA)检测尿中Survivin的方法,并探讨尿中Survivin和溶酶体相关蛋白跨膜4β(LAPTM4B)的诊断价值。 ),包括膀胱癌(BC)和肾细胞癌(RCC)。基于MPs的CLEIA是在双抗体夹心免疫反应和luminol-H2O2化学发光系统的基础上开发的。优化并评估了该方法的参数。从200例BC患者,81例RCC患者和114例健康个体中获取尿液样本,并采用基于MPs的CLEIA方法检测其尿中的Survivin。同时,测量了BC患者,RCC患者和健康对照者的尿LAPTM4B水平。分别和联合评估了尿中survivin和LAPTM4B在BC和RCC中的诊断效率。建立了一种基于MPs的一步法CLEIA,可准确,准确地检测尿中生存素。信号取决于存活蛋白浓度(0至200 ng / ml),检出限为0.949 ng / ml。尿中生存素的受体工作特征曲线(AUC)下的面积在BC为0.771,在RCC为0.763。尿存活蛋白与BC的肿瘤分期(P = 0.002),淋巴结转移(P = 0.017),远处转移(P = 0.005)和肿瘤大小相关(P = 0.02)。但是,未发现与RCC中的临床病理参数相关。尿LAPTM4B的AUC在BC为0.738,在RCC为0.704。它们的AUC组合在BC中为0.842,在RCC中为0.920。基于MPs的CLEIA在检测尿中生存素方面表现良好。尿存活蛋白和LAPTM4B可以作为潜在的生物标志物,用于BC和RCC的初步诊断,并且组合起来可以实现更好的诊断性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号